Relevium Engages PipeDreemz as Lead ACMPR Consultant for Biocannabix
Relevium Technologies Inc. (TSX.V:RLV (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has engaged PipeDreemz as lead consultant (the “Consultant”) for the Biocannabix Health Corp (“BHC”) ACMPR applications to Health Canada to obtain the necessary licenses. Biocannabix will focus on organic products and on the development of specialty genetic strains targeting primarily cannabidiol (CBD) and cannabigerol (CBG) for use in medical applications as well as consumer packaged goods.
Highlights
- Industry veteran Georges Routhier and PipeDreemz have been providing advisory services to a number of successful Licensees
- Instrumental in designing the H2 Biopharma facility in Lachute, Qc., acquired by Aurora Cannabis
- The PipeDreemz team holds advanced degrees in science, engineering, business, agriculture, horticulture and plant sciences
- As at January 1, 2018 PipeDreemz had 23 highly advanced facilities under construction across Canada
- ACMPR license application submission forecasted for Summer 2018
Aurelio Useche, CEO of Relevium stated: “Since the creation of Biocannabix Health Corp, a wholly-owned subsidiary of Relevium, we have interviewed a multitude of cannabis consultants, key industry suppliers and advisors with a focus on the Quebec market.” Mr. Useche continued: “We are extremely pleased to partner with George Routhier and the team at PipeDreemz who were highly recommended by industry insiders. George is a veteran in the industry, has a proven track record and shared values with Relevium in terms of the evolution of the cannabis business both in Canada and around the world.”
The Company will begin working immediately with the PipeDreemz and its advisors in the evaluation of selected locations in and around Montreal, Quebec, where the company will host its operations. All facets of the operations, from HVAC to security, genetics and micropropagation, to distribution and branding will be taken into consideration in order to ensure aligned strategic fit and the best possible long-term ROI for the company and its shareholders.
The Company anticipates that the application will be deposited to Health Canada before July 31, 2018.
More about PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
PipeDreemz cemented its position as an expert in the cannabis field following the sale of a PipeDreemz designed state-of-the-art, 49,000 square foot cannabis production facility to Aurora Cannabis Inc. H2 Biopharma retained PipeDreemz for start to finish services including design and oversight on construction of the facility, located in Lachute, Quebec. Aurora Cannabis Inc. acquired the PipeDreemz designed facility from H2 Biopharma in November 2017.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
